The global cardiac troponin market is on a steady growth path. Fortune Business Insights values the market at $3.50 billion in 2025, rising to $3.78 billion in 2026, and projects it will reach $7.17 billion by 2034 — a compound annual growth rate of 8.30% across the 2026–2034 forecast window. North America led the industry in 2025, holding a 41.15% share of global revenue.
Cardiac troponin refers to two regulatory proteins, troponin I (cTnI) and troponin T (cTnT), that govern calcium-driven interaction between actin and myosin in heart muscle. Because these proteins are highly specific to cardiac tissue, they serve as the leading biomarkers for detecting myocardial injury, and rising or falling levels help clinicians distinguish acute myocardial infarction from chronic heart conditions. Growing knowledge of these biomarkers, paired with advances in testing technology, has driven wider clinical adoption.
Growth Drivers
The expanding burden of cardiovascular disease is the market's core growth engine. As the population of patients with heart-related conditions increases, troponin testing is used ever more routinely to catch myocardial injury early. Research cited in the report notes that acute myocardial infarction affects roughly 3 million people worldwide, with over a million U.S. deaths annually, and separate data indicates U.S. heart attacks occur at a rate of about one every 40 seconds.
An aging global population reinforces this trend. Older adults face substantially higher rates of hypertension, heart disease, and stroke, and the report highlights sharp projected growth in the elderly U.S. population through 2040, which is expected to sustain long-term demand for cardiac diagnostics.
Innovation among manufacturers is another driver. Companies are rolling out new high-sensitivity and point-of-care (POC) assays to capture unmet clinical need — for example, regulatory clearances for next-generation troponin tests from major diagnostics firms have expanded the pool of available products. The COVID-19 pandemic also left a lasting mark: because acute cardiac injury was frequently observed in COVID-19 patients, demand for troponin testing rose sharply during the pandemic years, dipped briefly in 2021 as testing volumes fell, and has since resumed consistent growth.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-troponin-market-101234
Restraints
Despite this momentum, conventional troponin assays face a notable limitation: they lack the sensitivity to detect small quantities of the protein circulating in blood during the first few hours after a heart attack, which can delay diagnosis and constrain broader adoption of older-generation tests.
Market Segmentation
By protein type, troponin I is set to lead with roughly 73% of the market in 2026, owing to its high specificity and the growing availability of point-of-care products, while troponin T is expected to post strong growth as regulatory approvals expand and its use in routine heart-failure screening increases.
By testing setting, laboratory testing is projected to account for close to three-quarters of the market in 2026, since lab-based analysis offers greater precision than point-of-care alternatives. Point-of-care testing, however, is expected to grow at the fastest rate going forward, aided by rising use in resource-limited settings and a steady stream of newly approved devices.
By clinical indication, acute coronary syndrome is expected to represent just over half of market revenue in 2026, reflecting the biomarker's established diagnostic role; myocardial infarction ranks as the next-largest indication segment.
By end user, hospitals and clinics are set to hold roughly 63% of the market in 2026, driven by rising cardiovascular disease awareness and elevated hospital admissions, while diagnostic laboratories are expected to see solid growth as outsourced testing expands, particularly in developing markets.
Regional Insights
North America remains the largest regional market, generating about $1.44 billion in 2025 on the back of high disease prevalence, favorable reimbursement policies, and strong regulatory approval activity. Europe ranks second, supported by widespread adoption of high-sensitivity assays and a strong base of established manufacturers. Asia Pacific is expected to be the fastest-growing region, fueled by rising cardiovascular disease rates, new product launches, and expanding diagnostic infrastructure across countries such as China, Japan, and India.
Competitive Landscape
The market is moderately competitive. F. Hoffmann-La Roche Ltd. holds a leading position on the strength of its broad troponin product portfolio and ongoing biomarker expansion efforts. Other major participants include Abbott, bioMérieux SA, Siemens Healthineers, Beckman Coulter, QuidelOrtho, and PerkinElmer, many of which are pursuing new product launches, partnerships, and acquisitions to strengthen their market position.